JPMorgan Chase & Co. has raised its price target for HCA Healthcare (NYSE:HCA) from $420.00 to $535.00, suggesting a potential upside of 1.52% from its current price. HCA holds a consensus “Moderate Buy” rating with an average analyst target of $530.77. The company recently exceeded quarterly EPS estimates but slightly missed revenue projections, while setting an FY2026 EPS guidance above analyst forecasts.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
HCA Healthcare (NYSE:HCA) Given New $535.00 Price Target at JPMorgan Chase & Co.
JPMorgan Chase & Co. has raised its price target for HCA Healthcare (NYSE:HCA) from $420.00 to $535.00, suggesting a potential upside of 1.52% from its current price. HCA holds a consensus “Moderate Buy” rating with an average analyst target of $530.77. The company recently exceeded quarterly EPS estimates but slightly missed revenue projections, while setting an FY2026 EPS guidance above analyst forecasts.